Free tool
FAERS Monitor: Synjardy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206111 or its brand name (Synjardy, Empagliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,950
Serious
1,857
63% of reports
Hospitalization
986
Death reported
112
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea213
- blood glucose increased192
- vomiting189
- diarrhoea158
- diabetic ketoacidosis156
- weight decreased144
- fatigue131
- ketoacidosis124
- drug ineffective117
- dizziness109
- off label use101
- decreased appetite88
- asthenia87
- pain87
- urinary tract infection85
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 4 |
| 2016 | 58 |
| 2017 | 116 |
| 2018 | 185 |
| 2019 | 291 |
| 2020 | 300 |
| 2021 | 300 |
| 2022 | 358 |
| 2023 | 413 |
| 2024 | 350 |
| 2025 | 289 |
| 2026 | 285 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ketoacidosisSignal | 124 | 120.1 | 101.0 | 14,293 |
| diabetic ketoacidosisSignal | 156 | 46.6 | 40.0 | 6,879 |
| blood glucose increasedSignal | 192 | 7.3 | 6.3 | 1,041 |
| weight decreasedSignal | 144 | 3.7 | 3.1 | 282 |
| urinary tract infectionSignal | 85 | 3.6 | 2.9 | 155 |
| vomitingSignal | 189 | 2.9 | 2.5 | 233 |
| decreased appetiteSignal | 88 | 2.7 | 2.2 | 94 |
| nausea | 213 | 1.9 | 1.7 | 96 |
| diarrhoea | 158 | 1.7 | 1.5 | 51 |
| asthenia | 87 | 1.6 | 1.3 | 22 |
| dizziness | 109 | 1.6 | 1.3 | 22 |
| fatigue | 131 | 1.2 | 1.0 | 4 |
| pain | 87 | 1.0 | 0.8 | 0 |
| off label use | 101 | 0.8 | 0.7 | 4 |
| drug ineffective | 117 | 0.6 | 0.5 | 26 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.